The presence of the MYOM3 fragments in serum of DMD and LGMD2D patients and their respective mouse models prompted us to evaluate the utility of these biomarkers for monitoring the response to experimental therapies in mdx and KO-Sgca mice. This evidence concerns the gene MYOM3 and autosomal recessive limb-girdle muscular dystrophy type 2D.